

CENTRE DE RECHERCHE PUBLIC Genomics Research Unit



Interplay between microRNAs, Transcription Factors, and Target Genes: Linking Dynamic Expression Changes to Function

Petr Nazarov

23-07-2013

Nazarov, Reinsbach et al. Nucleic Acids Res. 2013, 41(5):2817-31

Genomics Research Unit, CRP-Santé







Nazarov PV, Reinsbach SE, Muller A, Nicot N, Philippidou D, Vallar L, Kreis S. Interplay of microRNAs, transcription factors and target genes: linking dynamic expression changes to function.

Nucleic Acids Res. 2013; 41(5):2817-31.



Genomics Research Unit, CRP-Santé



MicroRNAs



Small, non-coding RNAs (~22 nt)
Negative post-transcriptional regulators

◆Pre-miR → 2 strands, historically called guide and passenger strands. However passenger may be of equivalent importance.


Involved in many cellular processes and diseases. ~ 60% of genes are regulated by miRNAs.

- Roles in cancer:
- → tumour-suppressing miRNAs (miR-15a)
- → oncogenic miRNAs (miR-21)

Reinsbach, et al.(2012) RNA Biology

Genomics Research Unit, CRP-Santé

Canonical miRNA production. Adapted from Winter, Nat.Cell Biol. 2009









miRNAs are short and in principle may be not entire complementary to target gene mRNA sequence. This hampers prediction of target gene, and results in a high level of FPs.

miRNA expression depends on cell type and biological condition.

Precise mechanisms of miRNA actions are debated.

Understanding of mechanisms: cross-sectional studies may not provide enough information (cause-response problem), therefore **dynamic regulation of miRNA expression** changes have to be considered to answer this question.






The aim of the our study was to integrate time-resolved **miRNA**, **mRNA** data and existing **knowledge** about their interaction and functions in order to obtain new information about biological processes.

- Find robust list of miRNA-targeted genes: miR | mRNA
- Compose/verify a pipeline for analysis of time-resolved MA data
- Investigate dynamics of active biological functions in IFNγstimulated melanoma cell line
- Integrate miRNA, mRNA and inferred upstream transcription regulators
- Detect topological motifs in regulation network



EXPERIMENTAL DESIGN






Genomics Research Unit, CRP-Santé





Human melanoma **A375** cells were seeded together and cultured until sample collection. Cells were IFNγ stimulated at different time points.




Genomics Research Unit, CRP-Santé





Standard pre-processing scheme was used in **Partek® GS** (alternatively one can use APT)




It can be beneficial to remove lowly expressed features

Features with expression (log2 signal intensity) constantly below a certain threshold may be removed.

This improves number of significant DEG
 and improves qPCR validation afterwards.


Based on these profiles and our previous experience we selected threshold = 7





PCA: DATA OVERVIEW






Genomics Research Unit, CRP-Santé



ANALYSIS PIPELINE





Genomics Research Unit, CRP-Santé



CO-EXPRESSION ANALYSIS




Analysis was performed using a user-friendly tool CoExpress:


🦓 | 100


Gene Symbol: MITE


1 3850

http://www.bioinformatics.lu/CoExpress/









Genomics Research Unit, CRP-Santé




CO-EXPRESSION ANALYSIS



Analysis was performed using a user-friendly tool CoExpress:

http://www.bioinformatics.lu/CoExpress/




Top co-expressed miRNAs:





http://www.bioinformatics.lu/CoExpress/

Because of the lack of independent points we cannot use co-expression as a discovery tool. However CE analysis can be combined with existing knowledge:




TargetScan v6: we observed **398** <u>predicted</u> miRNA – | mRNA interactions (with r < -0.9) **TarBase v6:** we observed **17** <u>known</u> miRNA – | mRNA interactions (with r < -0.9)



ANALYSIS PIPELINE






Genomics Research Unit, CRP-Santé



DIFFERENTIAL EXPRESSION ANALYSIS





We tested several DEA methods, applicable for time course MA data

- Limma (linear models for microarray data) → Smyth, GK (2005). Limma: linear models for microarray data
- ◆ BETR (Bayesian Estimation of Temporal Regulation) → Aryee, MJ (2009) BMC Bioinformatics
- timecourse R-pkg (multivariate empirical Bayes models) → Tai YC, Speed TP (2006) Annals of Statistics

Genomics Research Unit, CRP-Santé




DIFFERENTIAL EXPRESSION ANALYSIS



Data for Benchmarking

Datasets + 200 permutations:





miRNA data x200

Synthetic data

Synthetic data set consisted of 700 features.

- 350 of those represented various profiles (peak, smooth peak, steep regulation, smooth regulation, linear) mixed with normal noise in different proportions, so that average r2 of profiles and noisy data varied between 0.999 and 0.5.
- > Another 350 features were **completely random**.





x200

Genomics Research Unit, CRP-Santé



Data

DIFFERENTIAL EXPRESSION ANALYSIS



Benchmarking Results

a + 200 permutations:		miRN	miRNA data		data	Synthetic data*			
	limma	1. miRN	A data set	2. mRN	A dataset	3. Synthetic dataset			
	Desired FDR	Significant	Permut. FDR	Significant	Permut. FDR	Significant	Permut. FDR	Real FDR	
\odot	0.001	65	0.001	4681	0.000	218	0	0.000	
	0.01	92	0.003	7935	0.000	261	0	0.004	
	0.05	115	0.005	10766	0.001	305	0	0.046	

	betr	1. miRN	A data set	2. mRN	A dataset	3. Synthetic dataset			
	Desired FDR	Significant	Permut. FDR	Significant	Permut. FDR	Significant	Permut. FDR	Real FDR	
8	0.001	98	0.106	11485	0.078	365	0.023	0.142	
	0.01	104	0.136	12533	0.105	392	0.033	0.184	
	0.05	109	0.164	13370	0.133	432	0.042	0.229	

	timecourse	1. miRN	A data set	2. mRN/	A dataset	3. Synthetic dataset			
	Desired FDR	Significant	Permut. FDR	Significant	Permut. FDR	Significant	Permut. FDR	Real FDR	
?	0.001	25	0.001	461	0.001	520	0.001	0.352	
	0.01	38	0.009	1778	0.010	562	0.010	0.391	
	0.05	68	0.050	8022	0.050	606	0.049	0.426	


(*) Synthetic data set consisted of 700 features. 350 of those represented various profiles (peak, smooth peak, steep regulation, smooth regulation, linear) mixed with normal noise in different proportions, so that average r2 of profiles and noisy data varied between 0.999 and 0.5. Another 350 features were completely random.

Genomics Research Unit, CRP-Santé



DIFFERENTIAL EXPRESSION ANALYSIS








mRNA

miR




University of Luxembourg

Genomics Research Unit, CRP-Santé










	Gene	Complex	3h	12h	24h	48h	72h	<expr></expr>	FDR
	DICER1	RISC	0.078	-0.209	-0.179	0.645	0.880	10.4	6.0E-08
/	DGCR8	Drosha	-0.056	-0.366	-0.065	0.520	0.604	8.4	8.6E-07
	EIF2C2 (Ago2)	RISC	-0.157	-0.351	0.162	0.562	0.569	9.0	5.3E-06
	RNASEN	Drosha	-0.009	-0.159	-0.239	-0.227	-0.254	10.3	8.2E-03

Genomics Research Unit, CRP-Santé



ANALYSIS PIPELINE





Genomics Research Unit, CRP-Santé



FUNCTIONAL ANALYSIS



DEA miRNA:mRNA -> Ingenuity [®] PA functional annotation Fisher's exact test,		iched fu ith FDR •		→	Combin categ		
Benjamini-Hochberg correction	3h/ctrl	12h/ctrl	24h/ctrl	48h/ctrl	72h/ctrl	JII ctrl/ctrl	
	5.2e-4	5.4e-4	1.2e-2	n/s	4.1e-3	2.6e-2	Gene Expression
al and a star and a star	1.7e-3	1.5e-3	4.0e-3	n/s	n/s	4.3e-2	Cell Signalling
43e44 12e33 31e43 n/s 13e33 22e42 Hematological Disease 61e44 31e43 r/s 15e34 3.4e3 Hematological Disease 61e44 31e43 r/s 15e34 3.4e3 Hematological Disease 63e645 36e40 10e20 r/s n/s n/s r/s	6.1e-4	1.3e-5	1.6e-2	n/s	n/s	4.3e-2	Cell-mediated Immune Response
3.903 6.5e.03 1.8e.02 n/s 3.5e.02 3.2e.02 Next 2 Respiratory Disease 3.8e.03 1.9e.02 n/s n/s n/s 4.3e.02 Lymphoid Tissue Structure and Development 7.7ex01 6.5e.03 3.1e.02 n/s 3.5e.02 Connective Tissue Oevelopment and Function	6.1e-4	1.3e-5	6.1e-4	n/s	n/s	1.6e-2	Immune Cell Trafficking
13e03 6.5e03 3.1e02 3.9e02 2.3e02 4.3e02 Organ Development	4.5e-3	1.5e-3	8.7e-3	1.6e-2	2.0e-2	1.8e-2	Molecular Transport
328-01 546-01 12e-02 nis 4.1e-03 2.6e-02 Gene Expression 16e-03 16e-03 46e-04 nis nis 4.3e-02 Cell Signaling 26e-02 16e-03 16e-02 15e-02 16e-03 16e-03 26e-02 16e-03 16e-03 16e-03 16e-03 16e-03	9.2e-6	7.4e-13	8.8e-5	2.1e-2	1.1e-3	4.3e-2	Infectious Disease
nis 1.2-33 2.7+04 1.2+02 1.7+03 5.1+03 Metabolic Disease 1.8+02 2.2+06 2.1+04 4.4444 4.44646 1.54666 4.8+03 Neurological Disease 2/2+06 7.4+03 8.8+05 2.1+02 1.2+03 4.3+02 1.1+02 1.0+0210	8.7e-6	1.5e-18	3.4e-6	8.3e-3	2.1e-2	5.0e-3	Immunological Disease
1 8e-02 12e-04 3 1e-02 n/s n/s 4.3e-02 Tissue Morphology 1 8e-03 56-061 2 e-02 n/s 2.3e-02 n/s Tumor Morphology 56-668 52-07 1 4e-07 2 1e-02 1-3e-02 51-63 Connective Tissue Disorders	9.5e-5	3.2e-10	1.4e-7	7.1e-4	1.3e-2	5.1e-3	Inflammatory Disease
2.0e-06 3.9e-14 3.3ee-11 7.9e-03 1.5e-02 3.7e-03 Dermatological Diseases and Conditions 9.5e-05 3.2e-10 1.4ee-07 7.1e-04 1.3e-02 6.1e-03 Inflammatory Disease	1.9e-3	1.7e-4	5.4e-4	n/s	n/s	2.4e-2	Inflammatory Response
5 5-00 52-010 148-07 48-04 5 1 + 03 Skeletal and Muscular Disorders 8 7-06 15-918 3 4+06 9 8-04 5 1 + 03 Skeletal and Muscular Disorders 8 7-06 15-918 3 4+06 9 8-04 5 1 + 03 Skeletal and Muscular Disorders 8 8-03 45-93 16 - 93 16 - 93 16 - 93 16 - 93	2.0e-6	3.9e-14	3.3e-11	7.9e-3	1.5e-2	3.7e-3	Dermatological Diseases and Conditions
18-03 26-03 22-04 n/n n/n 26-22 Ophthalmic Disease 18-041 23-05 51-64 n/n 15-03 16-02 Hematological System Development and Function 18-044 13-05 51-64 n/n 16-02 Hematological System Development and Function 18-043 13-05 51-64 n/n n/n 15-6-22 18-040 6-66 4-66 17-66 1-6-02 Cell Death and Survival	1.0e-2	6.5e-3	3.1e-2	4.7e-2	n/s	2.6e-2	Hair and Skin Development and Function
19e-03 17e-04 54e-04 n/s n/s 2.4e-02 Inflammatory Response 4.5e-03 1.5e-03 8.7e-03 1.6e-02 2.0e-02 1.8e-02 Molecular Transport	1.8e-2	5.6e-4	2.0e-2	n/s	2.3e-2	n/s	Turnor Morphology
51640 13657 516-92 n/s 4.3e-92 Cell-mediated Immune Response 18e-02 31693 n/s n/s 376-02 Cell-mediated Immune Response 56-903 20x945 n/s n/s n/s Arbitricrobial Response	n/s	1.3e-13	2.7e-4	1.2e-2	1.7e-3	5.1e-3	Metabolic Disease
10e-02 6 50-03 3 1e-02 4.7e-02 n/s 2.6e-02 Hair and Skin Development and Function	3.8e-5	1.4e-6	6.4e-6	2.6e-4	1.1e-4	9.1e-3	Cell Death and Survival
18e-02 13e-03 13e-03 7.te-04 2.te-02 4.3e-02 Organismal Injury and Abnormalities 18e-02 4.0e-04 56e07 3.5e405 1.4e-04 4.3e-02 Cellular Assembly and Organization	6.1e-4	3.1e-3	3.0e-4	4.6e-3	2.3e-3	2.6e-2	Cell Morphology
18-62 40-64 55-677 35-65 14-64 43-62 Cellular Function and Maintenance 27-603 15-62 55-677 35-65 24-64 43-62 Narous System Development and Function 77-64 55-65 55-67 35-65 24-64 15-62 Tissue Development	4.3e-4	3.0e-4	1.8e-4	2.5e-3	8.3e-4	7.9e-3	Cellular Development
15-63 15-645 55-677 35-845 24-640 15-862 Cell-To-Cell Signaling and Interaction 13-63 12-643 13-665 31-644 15-622 Organismal Development 65-63 15-642 65-63 15-642 Renal and Urological System Development and Function	4.3e-4	3.0e-4	2.2e-5	7.7e-4	6.8e-4	1.5e-2	Cellular Growth and Proliferation
1.8e-02 4.4e-02 8.7e-03 1.6e-02 2.0e-02 1.8e-02 Amino Acid Metabolism n/s n/s 4.0e-03 n/s n/s n/s Nutritional Disease	1.5e-3	1.6e-5	5.6e-7	3.4e-5	2.4e-4	1.8e-2	Cell-To-Cell Signalling and Interaction
4.3e-04 3.0e-04 2.3e-05 7.6e-04 6.8e-04 1.5e-02 Cellular Growth and Proliferation	7.7e-4	6.3e-5	5.6e-7	3.4e-5	2.4e-4	1.5e-2	Tissue Development
New J Steed Steed <th< td=""><td>1.8e-2</td><td>4.0e-4</td><td>5.6e-7</td><td>3.4e-5</td><td>1.4e-4</td><td>4.3e-2</td><td>Cellular Assembly and Organisation</td></th<>	1.8e-2	4.0e-4	5.6e-7	3.4e-5	1.4e-4	4.3e-2	Cellular Assembly and Organisation
ns 9.7e03 13e02 5.2e33 11e02 nie Protein Synthesis 4.3e04 37e05 Cancer Cancer Cancer 15e02 15e04 15e02	n/s	2.2e-2	1.4e-2	5.2e-3	1.1e-2	n/s	Post-Translational Modification
4.8e-04 1.3e-05 7.2e-06 1.1e-07 9.3e-08 3.7e-03 Cellular Movement 1.8e-03 1.3e-13 2.0e-08 1.1e-11 3.1e-14 5.1e-03 Gastrointestinal Disease	n/s	9.7e-3	1.4e-2	5.2e-3	1.1e-2	n/s	Protein Synthesis
6.7e-03 14+e03 14-e65 44-e67 12-e67 26-e62 26-e62 Reproductive System Disease n/s 44-e62 12-e62 36-e63 45-e62 43-e62 egyschological Disorders 18-e62 2-e62 22-e83 24-e62 20-e60 in Lipid Metabolism	4.3e-4	3.7e-5	8.1e-13	1.3e-14	2.9e-14	3.7e-3	Cancer
18-02 16-02 22003 16-02 2000 18-02 Small Molecularity 18-02 16-02 22003 16-02 Small Molecularity Small Molecular Disease 68-04 71-84 58-04 16-02 Cardiovascular Disease	4.8e-4	1.3e-5	7.2e-6	1.1e-7	9.4e-8	3.7e-3	Cellular Movement
bseed / feed seed	2.6e-2	1.0e-2	3.8e-3	8.1e-3	1.7e-3	4.3e-2	Cell Cycle


Genomics Research Unit, CRP-Santé



FUNCTIONAL ANALYSIS

Using P-value and Z-score (only Top 50)






Genomics Research Unit, CRP-Santé



ANALYSIS PIPELINE






Genomics Research Unit, CRP-Santé



UPSTREAM REGULATORS





Importantly, inferred upstream regulators include: **miRNAs, TFs, kinases**, chemical, etc. Therefore we included protein level into our analysis.




VISUALISATION OF INTEGRATED DATA



- Significantly expressed genes are combined into functional categories
 miRNA targeting activated TR are selected
 Connections show: TR -> mRNA
 - miR -| TR


miR -| mRNA




Genomics Research Unit, CRP-Santé

VISUALISATION OF INTEGRATED DATA







Genomics Research Unit, CRP-Santé


Development

Cell-To-Cell Signalin And Interactio





Networks, interconnecting: genes, miRNAs and transcription factors (inferred by Ingenuity), were manually curated. We were able identify several feed forward loops, presented below.



Genomics Research Unit, CRP-Santé







Biology

We observed a delayed response of miRNA with respect to mRNA response to IFNγ stimulation

 \rightarrow miRNA are involved in fine tuning and compensation

Promising regulation motifs were detected

Analysis

Pipeline for simultaneous analysis of time-resolved miRNA and mRNA data was validated

We showed benefits of LIMMA and filtering of not expressed features: lower FP rate and higher number of SDE genes.



ACKNOWLEDGEMENTS

Fonds National de la Recherche Luxembourg





CENTRE DE RECHERCHE PUBLIC



Arnaud Muller



Nathalie Nicot



aurent Vallar

Stephanie Kreis



UNIVERSITÉ DU LUXEMBOURG



Susanne Reinsbach



Demetra Philippidou

Genomics Research Unit, CRP-Santé